Testing CD-RCHOP for DLBCL with TP53 and chromosome 17p changes
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of chemotherapy drugs (CD-RCHOP) for people with a specific type of large B-cell lymphoma that has both a TP53 gene mutation and a missing piece of chromosome 17. It aims to see if this treatment can help those whose lymphoma has these particular genetic features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma that is CD20 positive.
- Your lymphoma must test positive for both a TP53 gene mutation and a missing part of chromosome 17 (called del(17p)).
- You must be between 18 and 75 years old.
- You must be well enough to perform daily activities with little or no help (ECOG score 0, 1, or 2).
- You must have never had cancer before or have any other cancers right now.
- You must have not received any previous treatment for this lymphoma, including chemotherapy or stem cell transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
This trial tests a way to use your tumor's DNA (called ctDNA) to choose a targeted treatment for your newly diagnosed DLBCL. It aims to see if this personalized approach works better than standard care.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.